Goal
Provide a broad-spectrum antiviral therapeutic for viruses such as Ebola, HIV, and others.
Problem
Lack of effective drugs for emerging viral infections (Ebola, HIV, H1N1) and drug-resistant strains.
Concept Summary
Hexamminecobalt(III) chloride (CoHex) is a kinetically inert, water-soluble cobalt(III) complex that interacts with biological systems primarily through outer-sphere coordination and electrostatic forces. Laboratory studies report inhibition of protein synthesis, dose-dependent antiviral activity against a wide range of viruses (ssRNA, dsRNA, dsDNA, enveloped and non-enveloped), and lower cytotoxicity than approved drugs such as cis-platin.
Principles
- outer-sphere coordination
- electrostatic interaction
- kinetic inertness of Co(III) complex
- protein synthesis inhibition
Scientific Domains
Materials
- hexamminecobalt(III) chloride
- cobalt(III) complex
- ammonia ligands
- chloride ions
Mechanisms of Action
- outer-sphere coordination with viral components
- electrostatic interaction disrupting viral replication
- steric blockade of protein synthesis
- inhibition of viral protein synthesis
Applications
- Therapeutic treatment of viral infections (Ebola, HIV, influenza)
- First-responder stockpiles for outbreak response
- Adjunct therapy to reduce dosage of existing antivirals
Claimed Performance
Broad-spectrum antiviral activity against Sindbis, HIV-1, Zaire Ebola virus, and many other ssRNA, dsRNA, dsDNA viruses; lower cytotoxicity than FDA-approved cis-platin; additive effect with existing antiviral drugs.
Experimental Evidence
Initial in-vitro studies show inhibition of Sindbis, HIV-1 and Ebola viruses; small-animal testing indicates much lower cytotoxicity than cis-platin; reported by Naval Research Laboratory and US Navy.
Replication Status
Reported by Naval Research Laboratory and patents; no independent replication documented in the article.
Limitations
- Limited pre-clinical data; no human clinical trials reported
- Regulatory approval pathway not addressed
- Scale-up and manufacturing costs not discussed
Red Flags
- Claims are based on early-stage pre-clinical data only
